Pipeline — registered trials by phase
MiCLASP Post Market Clinical Follow-Up (PMCF) Study
— · Mitral Regurgitation, Mitral Insufficiency · Active Not Recruiting · est. 2025-09-04
CARDINAL Adjustable Annuloplasty Ring System For Treatment of Mitral Regurgitation
— · Mitral Valve Insufficiency · Completed · est. 2012-02
SOURCE 3: Observational Study to Evaluate Safety and Performance of SAPIEN 3 THV System in Real Life Practice
— · Aortic Stenosis · Completed · est. 2016-02
CLAARITY is a Prospective, Observational, Single-arm, Multi-center, Post-market US Study Designed to Evaluate the Safety and Performance of the ECLIPTIS Left Atrial Appendage Exclusion System for Exclusion of the Left Atrial Appendage (LAA) During Concomitant Open-heart Cardiac Surgery.
— · Atrial Appendage · Not Yet Recruiting · est. 2027-07-10
ClearSight System CHN Study
— · Patient With Clinically Indicated Invasive Monitoring · Completed · est. 2019-10-17
Clinical Study of Edwards Cardioband FIT Valve Repair System
— · Tricuspid Regurgitation · Active Not Recruiting · est. 2026-12-31
Hypotension Prediction Index Study (HPI Study)
— · Hypotension · Completed · est. 2020-03-17
China S3 PMS: SAPIEN 3 China Post Market Registry Study
— · Aortic Stenosis, Severe · Active Not Recruiting · est. 2035-12
CENTERA PMCF: Post-Market Follow-up of the CENTERA Transcatheter Heart Valve System
— · Aortic Valve Stenosis · Completed · est. 2019-08-14
Pediatric Cardiac Output Monitoring Observational Study
— · Pediatric ALL · Completed · est. 2023-01-05
PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - S3 Intermediate
— · Symptomatic Severe Aortic Stenosis · Completed · est. 2015-11-18
The SPACER Trial - Repair of Tricuspid Valve Regurgitation Using the Edwards TricuSPid TrAnsCatheter REpaiR System
— · Tricuspid Valve Regurgitation · Completed · est. 2018-01-30
The ENCIRCLE Trial
— · Mitral Regurgitation, Mitral Valve Insufficiency · Active Not Recruiting · est. 2027-10-10
Surgical Treatment of Aortic Stenosis With a Next Generation Surgical Aortic Valve
— · Aortic Valve Stenosis With Insufficiency, Aortic Valve Stenosis · Completed · est. 2017-12
PARTNER 3 Trial - Aortic Valve-in-Valve
— · Aortic Stenosis, Aortic Stenosis, Severe · Recruiting · est. 2033-01
Clinical Study of the Intravenous Blood Glucose System in Hospitalized Adult Elective or Non-Emergent Surgery and Medical/Surgical Intensive Care Unit Patients
— · Blood Glucose · Completed · est. 2010-04
Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial
— · Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease · Recruiting · est. 2027-12-31
Edwards EVOQUE Eos MISCEND Study
— · Mitral Valve Regurgitation (Degenerative or Functional) · Active Not Recruiting · est. 2028-04-30
Real World Data Collection on the INSPIRIS RESILIA Aortic Valve
— · Aortic Valve Disease · Recruiting · est. 2026-12
PREVAIL-TA: Placement of Aortic Balloon Expandable Transcatheter Valves Trial (Europe)
— · Aortic Valve Stenosis · Completed · est. 2011-02
Early Feasibility Study - Edwards APTURE Transcatheter Shunt System
— · Heart Failure · Recruiting · est. 2027-04
TVMR With the Innovalve System Trial - Pilot in Georgia
— · Mitral Valve Regurgitation (Degenerative or Functional) · Completed · est. 2025-01-01
KONECT RESILIA Aortic Valved Conduit (AVC) Real-world Study Assessing Safety and Performance
— · Aortic Valve Disease · Recruiting · est. 2028-12-31
ExCEED: CENTERA THV System in Intermediate Risk Patients Who Have Symptomatic, Severe, Calcific, Aortic Stenosis
— · Aortic Valve Stenosis · Active Not Recruiting · est. 2020-10-02
TRIFORMIS RESILIA Real-world Study Assessing Safety and Performance (TRIBLAZE Study)
— · Heart Valve Diseases, Heart Diseases, Cardiovascular Diseases · Not Yet Recruiting · est. 2030-08
No registered trials in this stage.
No registered trials in this stage.
No registered trials in this stage.
No approved products listed under this sponsor in Drugs@FDA (partnered or subsidiary products may be listed elsewhere).
Source: ClinicalTrials.gov (trials where Edwards Lifesciences is lead sponsor; 69 active or completed) and Drugs@FDA (0 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- 8-K2026-08-28Current report (material event)
- S-82026-08-04Employee stock plan
- 10-Q2026-08-04Quarterly report
- 8-K2026-07-23Current report (material event)
- 11-K2026-06-1211-K
- 11-K2026-06-1211-K
- SD2026-05-27SD
- 8-K2026-05-08Current report (material event)
- 10-Q2026-05-06Quarterly report
- 8-K2026-05-04Current report (material event)
- SCHEDULE 13G2026-04-29SCHEDULE 13G
- 8-K2026-04-23Current report (material event)
- SCHEDULE 13G/A2026-03-26SCHEDULE 13G/A
- DEFA14A2026-03-26DEFA14A
- ARS2026-03-26Annual report to holders
- DEFA14A2026-03-26DEFA14A
- DEF 14A2026-03-26Proxy statement
- 10-K2026-02-25Annual report
- 8-K2026-02-10Current report (material event)
- 8-K2026-01-12Current report (material event)
- 10-Q2025-11-05Quarterly report
- 8-K2025-10-30Current report (material event)
- 8-K2025-10-30Current report (material event)
- SCHEDULE 13G/A2025-10-17SCHEDULE 13G/A
- 8-K2025-08-19Current report (material event)
- SCHEDULE 13G/A2025-08-12SCHEDULE 13G/A
- S-82025-08-06Employee stock plan
- S-82025-08-06Employee stock plan
- 10-Q2025-08-06Quarterly report
- 8-K2025-08-06Current report (material event)
- 8-K2025-07-25Current report (material event)
- 8-K2025-07-24Current report (material event)
- S-3ASR2025-07-21S-3ASR
- 11-K2025-06-1711-K
- 11-K2025-06-1711-K
- SD2025-05-30SD
- 8-K2025-05-08Current report (material event)
- 10-Q2025-05-06Quarterly report
- 8-K2025-04-23Current report (material event)
- DEFA14A2025-04-14DEFA14A
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.